A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)
Understanding the molecular biological basis of chronic lymphocytic leukemia (CLL) pathogenesis and stratification of patients into risk groups has now led to significant advances in treatment. New targeted drugs with different mechanisms of action (bruton’s tyrosine kinase inhibitors, bCL-2 inhibit...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-11-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/587 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!